Nazanin Ghazanfari
Overview
Explore the profile of Nazanin Ghazanfari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ng S, De Labastida Rivera F, Yan J, Corvino D, Das I, Zhang P, et al.
Nat Immunol
. 2024 Feb;
25(4):716.
PMID: 38360937
No abstract available.
2.
Ghazanfari N, Gregory J, Devi S, Fernandez-Ruiz D, Beattie L, Mueller S, et al.
J Immunol
. 2021 Aug;
207(6):1578-1590.
PMID: 34400523
In the ANKA mouse model of malaria, accumulation of CD8 T cells and infected RBCs in the brain promotes the development of experimental cerebral malaria (ECM). In this study, we...
3.
Devi S, Alexandre Y, Loi J, Gillis R, Ghazanfari N, Creed S, et al.
Immunity
. 2021 Apr;
54(6):1219-1230.e7.
PMID: 33915109
The sympathetic nervous system (SNS) controls various physiological functions via the neurotransmitter noradrenaline. Activation of the SNS in response to psychological or physical stress is frequently associated with weakened immunity....
4.
Sedgwick A, Ghazanfari N, Constantinescu P, Mantamadiotis T, Barrow A
Front Immunol
. 2020 Sep;
11:1549.
PMID: 32903717
The brain is considered an immune privileged site due to the high selectivity of the blood-brain barrier which restricts the passage of molecules and cells into the brain parenchyma. Recent...
5.
Ng S, De Labastida Rivera F, Yan J, Corvino D, Das I, Zhang P, et al.
Nat Immunol
. 2020 Aug;
21(10):1205-1218.
PMID: 32839608
Immune-modulating therapies have revolutionized the treatment of chronic diseases, particularly cancer. However, their success is restricted and there is a need to identify new therapeutic targets. Here, we show that...
6.
Valencia-Hernandez A, Ng W, Ghazanfari N, Ghilas S, de Menezes M, Holz L, et al.
Cell Host Microbe
. 2020 May;
27(6):950-962.e7.
PMID: 32396839
Liver-resident memory CD8 T (T) cells remain in and constantly patrol the liver to elicit rapid immunity upon antigen encounter and can mediate efficient protection against liver-stage Plasmodium infection. This...
7.
Ghazanfari N, Mueller S, Heath W
Front Immunol
. 2018 Sep;
9:2016.
PMID: 30250468
Cerebral malaria (CM) is an acute encephalopathy caused by the malaria parasite , which develops in a small minority of infected patients and is responsible for the majority of deaths...
8.
Ghazanfari N, Trajanovska S, Morsch M, Liang S, Reddel S, Phillips W
Ann N Y Acad Sci
. 2017 Nov;
1412(1):54-61.
PMID: 29125188
While the majority of myasthenia gravis patients express antibodies targeting the acetylcholine receptor, the second most common cohort instead displays autoantibodies against muscle-specific kinase (MuSK). MuSK is a transmembrane tyrosine...
9.
Fernandez-Ruiz D, Lau L, Ghazanfari N, Jones C, Ng W, Davey G, et al.
J Immunol
. 2017 Nov;
199(12):4165-4179.
PMID: 29084838
We describe an MHC class II (I-A)-restricted TCR transgenic mouse line that produces CD4 T cells specific for species. This line, termed PbT-II, was derived from a CD4 T cell...
10.
Ghazanfari N, Linsao E, Trajanovska S, Morsch M, Gregorevic P, Liang S, et al.
Physiol Rep
. 2015 Dec;
3(12).
PMID: 26702075
We investigated the influence of postsynaptic tyrosine kinase signaling in a mouse model of muscle-specific kinase (MuSK) myasthenia gravis (MG). Mice administered repeated daily injections of IgG from MuSK MG...